Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathy - Overview
Diabetic Neuropathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Neuropathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Neuropathy - Companies Involved in Therapeutics Development
Achelios Therapeutics Inc
Applied Therapeutics Inc
Beijing Tide Pharmaceutical Co Ltd
Bexion Pharmaceuticals LLC
Celon Pharma SA
CSPC Pharmaceutical Group Ltd
Epigen Biosciences Inc
Exodos Life Sciences Limited Partnership
Frontbio Co Ltd
G&P Bioscience Co Ltd
Glycadia Inc
Grunenthal GmbH
Han Wha Pharma Co Ltd
Ion Channel Pharmacology LLC
JanOne Inc
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tabe Pharma Corp
Omeros Corp
Ono Pharmaceutical Co Ltd
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Releviate Therapeutics
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
WEX Pharmaceuticals Inc
Winsantor Inc
Zelira Therapeutics Ltd
Zhejiang Pharmaceutical Co Ltd
Diabetic Neuropathy - Drug Profiles
A-717 - Drug Profile
Product Description
Mechanism Of Action
atexakin alfa - Drug Profile
Product Description
Mechanism Of Action
BXQ-350 - Drug Profile
Product Description
Mechanism Of Action
caficrestat - Drug Profile
Product Description
Mechanism Of Action
CPL-207280CA - Drug Profile
Product Description
Mechanism Of Action
elismetrep - Drug Profile
Product Description
Mechanism Of Action
EPGN-2154 - Drug Profile
Product Description
Mechanism Of Action
FB-118B1 - Drug Profile
Product Description
Mechanism Of Action
GB-102 - Drug Profile
Product Description
Mechanism Of Action
GLY-230 - Drug Profile
Product Description
Mechanism Of Action
HSK-16149 - Drug Profile
Product Description
Mechanism Of Action
ketoprofen - Drug Profile
Product Description
Mechanism Of Action
KU-32 - Drug Profile
Product Description
Mechanism Of Action
lidocaine - Drug Profile
Product Description
Mechanism Of Action
MDR-16523 - Drug Profile
Product Description
Mechanism Of Action
MDR-652 - Drug Profile
Product Description
Mechanism Of Action
Monoclol Antibodies to Inhibit MASP-2 for Diabetic Complications and Rheumatoid Arthritis - Drug Profile
Product Description
Mechanism Of Action
NSI-189 - Drug Profile
Product Description
Mechanism Of Action
ONO-2910 - Drug Profile
Product Description
Mechanism Of Action
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Male Health - Drug Profile
Product Description
Mechanism Of Action
PGDN-20WS - Drug Profile
Product Description
Mechanism Of Action
pirenzepine - Drug Profile
Product Description
Mechanism Of Action
PTG-6 - Drug Profile
Product Description
Mechanism Of Action
PTG-640 - Drug Profile
Product Description
Mechanism Of Action
PTG-641 - Drug Profile
Product Description
Mechanism Of Action
resiniferatoxin - Drug Profile
Product Description
Mechanism Of Action
RLVT-1402 - Drug Profile
Product Description
Mechanism Of Action
RLVT-903 - Drug Profile
Product Description
Mechanism Of Action
RTA-901 - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Algodystrophy, Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Pain - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Diabetic Peripheral Neuropathy - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Agonize MOR1 for Chemotherapy Induced Peripheral Neuropathy, Diabetic Peripheral Neuropathy and Postherpetic Neuralgia - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize CB1 and CB2 for Diabetic Neuropathy and Peripheral Arterial Disease - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Target Plasminogen for Chronic Inflammatory Diseases and Diabetic Neuropathy - Drug Profile
Product Description
Mechanism Of Action
sodium nitrite SR - Drug Profile
Product Description
Mechanism Of Action
SYHA-1402 - Drug Profile
Product Description
Mechanism Of Action
Tetrodotoxin - Drug Profile
Product Description
Mechanism Of Action
UI-016 - Drug Profile
Product Description
Mechanism Of Action
UI-048 - Drug Profile
Product Description
Mechanism Of Action
YJ-001 - Drug Profile
Product Description
Mechanism Of Action
YJC-007 - Drug Profile
Product Description
Mechanism Of Action
Diabetic Neuropathy - Dormant Projects
Diabetic Neuropathy - Discontinued Products
Diabetic Neuropathy - Product Development Milestones
Featured News & Press Releases
Aug 02, 2021: Innovative drug HSK16149 capsule was approved to carry out phase II clinical trial of "auxiliary opioid algesia"
Jun 02, 2021: Innovative drug HSK16149 capsule new indications obtained IND application "Notice of Acceptance"
May 13, 2021: Pure Green Pharmaceuticals reports unexpected results of a randomized, placebo controlled clinical trial with sublingual CBD in patients with painful diabetic peripheral neuropathy
Apr 01, 2021: Celon Pharma announces CPL’280, second generation oral GPR40 agonist, meets primary endpoint in phase 1 trial
Jan 25, 2021: Sonnet BioTherapeutics announces the successful completion of a non-human primate toxicology study of SON-080
Sep 30, 2020: Praetego receives NIH phase 2 STTR funding to advance novel amadorin drug candidates for diabetic peripheral neuropathy
Apr 12, 2019: “SYHA1402” for the treatment of diabetic neuropathy was granted clinical trial approval
Jun 01, 2018: Reata Selected to Present on its Early-Stage Program RTA 901 at the BIO Intertiol Convention
Mar 16, 2018: Reata to Present on its Diabetic Neuropathy Drug Candidate RTA-901 at the BIO Asia Intertiol Conference
Aug 02, 2017: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
Sep 04, 2016: Salvianolic acid A tablets developed by the tiol Drug Screening Center received clinical approval
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Diabetic Neuropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Diabetic Neuropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Diabetic Neuropathy - Dormant Projects, 2022
Diabetic Neuropathy - Dormant Projects, 2022 (Contd..1)
Diabetic Neuropathy - Dormant Projects, 2022 (Contd..2)
Diabetic Neuropathy - Dormant Projects, 2022 (Contd..3)
Diabetic Neuropathy - Discontinued Products, 2022